Pharmacokinetic-Pharmacodynamic Model of Drugs and Their Pharmacokinetic Differences between Normal and Disease States

28K

views

130

authors

15

articles

Pharmacokinetic-Pharmacodynamic Model of Drugs and Their Pharmacokinetic Differences between Normal and Disease States

28K

views

130

authors

15

articles

Editorial

Frontiers in Pharmacology

Editorial: Pharmacokinetic-Pharmacodynamic Model of Drugs and Their Pharmacokinetic Differences between Normal and Disease States

Zipeng Gong

,

Ruixing Chen

,

Ling Ye

,

Guo Ma

, 1 more and

Kaustubh Kulkarni

86 views

0 citations

Editors

5

Zipeng Gong

Guizhou Medical University

Kaustubh Kulkarni

Blueprint Medicines

Yan-Fang Xian

The Chinese University of Hong Kong

Ling Ye

Southern Medical University

Guo Ma

Fudan University

Impact

About

This Research Topic is part of a series with:

Pharmacokinetic Differences of Drugs and Their Regulatory Mechanisms Under Dual Status Including Normal and Diseased Organism

In the main frame of the above research topic, 16 contributions have been published including but not limited to the comparative pharmacokinetics between normal and disease status, the changes in the expression and function of drug-metabolizing enzymes and drug transporters in disease status and their related regulatory mechanisms, ADME/toxicity of drugs as well as their regulation, drug-drug interactions mediated by nuclear receptors, transporters and metabolic enzymes based on the methods and techniques of pharmacokinetics, transcriptomics, and metabolomics. However , the pharmacokinetic study is not only crucial in the development of new drugs, but also the study of pharmacokinetic-pharmacokinetic(PK-PD) model plays an important role in the process of new drug development. PK-PD model can reveal the internal relationship between drug concentration and effect, help to understand the dynamic characteristics of the drug action site in vivo and deduce the action site producing effect and drug concentration at the action site, which enables researchers to recognize the comprehensive characteristics of drug PK and PD processes in vivo. However, preclinical pharmacokinetic data are mainly derived from healthy animals, which is unreasonable. On the one hand, patients are the final consumers of drugs because drugs are mainly used to treat patients with diseases. On the other hand, whether the body is in a pathological state and the severity of the disease have different effects on the ADMEof drugs, which is closely related to whether the clinical drug is safe and effective. Therefore, studying the pharmacokinetics and PK-PD model in disease states is more meaningful and clinically relevant.

Given the fact that drugs are mainly used in the body under disease states, this topic will not only continue to focus on pharmacokinetic differences of drugs including Traditional Chinese medicine and their regulatory mechanisms under normal and disease status but also focus on the study of drug PK-PD model based on the cellular pharmacokinetics and integrated pharmacokinetics. We hope to provide references and ideas for individualized safety and effective drug use, and optimizing the drug evaluation system based on disease states. In the present Research Topic, we will continue to welcome original research, reviews, and mini reviews articles, including but not limited to the following subjects:

•The pharmacokinetic differences of drugs including Traditional Chinese medicine and their mechanisms under normal and disease status.
• The study of cellular pharmacokinetics.
• The changes in the expression and function of drug-metabolizing enzymes and drug transporters in disease status and their related regulatory mechanisms.
•The study of intestinal microbiome mediated drug metabolism and its effect on drug efficacy and toxicity.
• ADME/toxicity of drugs as well as their regulation, drug-drug interactions mediated by nuclear receptors, transporters, and metabolic enzymes based on the methods and techniques of pharmacokinetics, transcriptomics, and metabolomics.
• The study of the drug PK-PD model based on cellular pharmacokinetics and integrated pharmacokinetics.

Download ebook

PDF

EPUB

Share

Editors

Zipeng Gong

Guizhou Medical University

Kaustubh Kulkarni

Blueprint Medicines

Yan-Fang Xian

The Chinese University of Hong Kong

Ling Ye

Southern Medical University

Guo Ma

Fudan University

Impact

28,023 Total views

20,796 Article views

6,275 Article downloads

952 Topic views

Published In

Frontiers in Pharmacology

Drug Metabolism and Transport

About Frontiers Research Topics

With their unique mixes of varied contributions from Original Research to Review Articles, Research Topics unify the most influential researchers, the latest key findings and historical advances in a hot research area! Find out more on how to host your own Frontiers Research Topic or contribute to one as an author.

Suggest a topic